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Sedation administration and agitation management are fundamental activities in any intensive care unit. A lack of objective measures of agitation and sedation, as well as poor understanding of the underlying dynamics, contribute to inefficient outcomes and expensive healthcare. Recent models of agitation-sedation pharmacodynamics have enhanced understanding of the underlying dynamics and enable development of advanced protocols for semi-automated sedation administration. However, these initial models do not capture all observed dynamics, particularly periods of low sedative infusion. A physiologically-representative model that incorporates endogenous agitation reduction (EAR) dynamics is presented and validated using data from 37 critical care patients. High median Relative Average Normalised Density (RAND) values of 0.77 and 0.78 support and minimum RAND values of 0.51 and 0.55 for models without and with EAR dynamics respectively show that both models are valid representations of the fundamental agitation-sedation dynamics present in a broad spectrum of ICU patients. While the addition of the EAR dynamic increases the ability of the model to capture the observed dynamics of the agitation-sedation system, the improvement is relatively small and the sensitivity of the model to the EAR dynamic is low. Although this may represent a limitation of the model, the inclusion of EAR is shown to be important for accurately capturing periods of low, or no, sedative infusion, such as during weaning prior to extubation. 
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Effective delivery of sedation in the intensive care unit (ICU) is fundamental to providing comfort and relief to the critically ill. A Midazolam and Morphine combination, given by intermittent bolus or infusion, is the mainstay of most ICU regimens [1]. Midazolam is a sedative agent used to induce a state of conscious sedation, and Morphine is a powerful opioid analgesic with additional mild sedative effects.

Insufficient sedation exacerbates anxiety and agitation, and increases the risk of self-extubation. Over-sedation is a common outcome, and is damaging to patient health, and increases length of stay and cost [2]. While sedation is administered to maintain patient comfort, most sedation in the ICU is administered in response to patient agitation [3]. Hence, the target, or control, metric for regulating sedation in critical care is minimal agitation, rather than a given level of consciousness.

Several recent studies have highlighted the cost and healthcare benefits of drug delivery protocols based upon agitation-sedation assessment scales [4-6]. Very simple sedation control protocols aimed at minimizing over-sedation have reduced length of stay 28–35%, total drug requirements 46–57%, and testing for altered mental status 67% [2, 7]. Therefore, controlling agitation without over-sedation offers significant potential. The key to achieving such control is accurate models that include all fundamental clearance pharmacodynamic behaviours.

Agitation-sedation cycling describes oscillations between states of agitation and over-sedation often observed in critically ill patients. The underlying non-linear dynamics of the agitation-sedation cycle are not well understood and many complex interactions contribute to observed patient behaviour. Therapeutic treatment methods rely heavily upon the experience and intuition of the medical staff, introducing variability and inconsistency. Computerized sedative infusion protocols that enable consistency of care and minimize fluctuations in treatment could therefore improve patient care, simplify administration, minimize drug consumption and staff effort, and reduce costs. 

In spite of these advantages, current computer assisted infusion systems utilising feedback control in the ICU are still in their infancy [8-10]. Target Controlled Infusion (TCI) systems deliver drugs to maintain target plasma concentrations, using a pharmacokinetic model. This approach is well suited to anaesthesia where short periods of reduced consciousness and well-known pharmacology are common. However, infusion systems that regulate the infusion rate to maintain target agitation levels, thus regulating the primary metric for long-term sedation, are the goal for improving care in the ICU.

Although conscious sedation in the ICU utilises hypnotic drugs similar to those used in Total Intra-Venous Anaesthesia (TIVA), the drug dose and consciousness levels are distinctly different, as are the patients and the environment. More importantly, the overall goal of the therapy is significantly different. Anaesthesia applications aim to induce reduced consciousness for short periods. However ICU sedation seeks to simultaneously minimise both agitation and over-sedation over long periods of time. Hence, critical care sedation management is a very different problem that seeks the best trade-off between sedative dose and patient agitation. Therefore, while similarities between the two fields may provide insight, the differences prevent simple application of anaesthesia delivery methods, measurements and protocols to long-term ICU sedation administration.

The primary limitations to the development of optimized sedative infusion protocols are the lack of an objective, physiologically-based, quantified agitation scale and limited understanding of the underlying system dynamics. The subjective measures of agitation currently employed introduce significant variability between assessors and inconsistency of care [5, 11]. While no gold-standard agitation-sedation scale exists, the Riker Sedation Agitation Scale (SAS) is widely accepted [12]. Quantitative agitation sensors being developed [13-16], offer the potential to significantly improve agitation management when coupled with dynamic models and control protocols [17]. This research further develops the physiologically-based models required to develop agitation feedback protocols for medical decision support systems and eventually automated sedation administration.

Previous attempts to improve agitation management in the ICU have been limited to clinical trials employing fixed sedative protocols using subjective agitation assessments [2, 4, 7, 18]. The use of quantitative modelling to enhance understanding of the system and provide a simulation platform is a recently developed tool in this area [10, 17, 19]. Initial models [17, 20] were built upon a simple 2-compartment pharmacokinetic framework and treated the concomitant administration of Morphine and Midazolam as one drug for pharmacokinetic purposes. The assumption of a linear relationship between plasma drug concentration and drug effect led to underestimation of the patient’s sedative requirements at higher doses. More complex dynamics including separate pharmacokinetics, effect saturation and drug synergism were added upon further development of the model [21, 22]. 





The model presented utilizes separate pharmacokinetic (PK) models for Midazolam and Morphine. Displayed schematically in Fig. 1, it is a closer representation of the actual physiological system than other works [17, 19, 20-22], and includes delayed distribution, drug synergism, effect saturation and endogenous agitation reduction. The model is defined in three main portions:





II. Pharmacokinetics of Midazolam:
			(4)
				(5)
III. Pharmacodynamics of Morphine and Midazolam:
			(6)
where Cc, Cp and Ce are the drug concentrations (mg/L) in the central, peripheral and effect compartments, Vc, Vp and Ve are the distribution volumes (L) of the central, peripheral and effect compartments, U is the intravenous infusion rate (mL/min), A is an agitation index, S is the stimulus invoking agitation, Kij is the transfer rate (L/min) from compartment i to compartment j, KCL is the drug clearance (L/min), KT is the effect time constant (min-1), and Po and Ps are the proportions of Morphine (‘o’) and Midazolam (‘s’) per unit volume of solution respectively (mg/mL). Time is represented by t (min),  is the variable of integration, and the terms w1 and w2(t) are the relative weighting coefficients between stimulus and sedative sensitivity. Similarly, w3 is the coefficient associated with the endogenous reduction of patient agitation, or agitation reduction without sedative. Finally, EComb is the combined pharmacodynamic effect of the individual effect site drug concentrations of Morphine and Midazolam determined using response surface modelling as defined in Minto et al. [23] and detailed in the lower portion of Fig. 1. In Fig. 1 and represent the concentrations at which Morphine or Midazolam would have 50% effect if administered alone. 

This model is intended to be the simplest necessary to capture the essential dynamics of the agitation-sedation system, matching patient observations and published literature with a physiologically representative model. Equations (1)–(2) represent the pharmacokinetics (PK) of the infusion and distribution of Morphine, and Equation (3) represents transport of Morphine to the effect site. Similarly, Equation (4) represents the pharmacokinetics of the infusion and distribution of Midazolam, and Equation (5) represents transport of Midazolam to the effect site. 

The non-linear pharmacodynamic (PD) Equation (6) is based on physiological observations of patient behaviour, and simply states that the rate of change of agitation depends upon the relative magnitude of the stimulus to the cumulative sedative effect and endogenous agitation reduction. Stimulus in this context refers to the combined effect of inherent pain, distress, or loss of inhibition caused by the diseased/injured state of the patient, and the therapeutic and diagnostic procedures performed by medical staff [21]. 

2.1.1 Pharmacokinetic (PK) Modelling
Many pharmacological models exist for the delivery of Morphine or Midazolam independently. Typically, Morphine and Midazolam are administered as a fixed ratio solution. Hence, this paper utilizes separate compartmental PK equations for each drug, so the combined drug infusion rate results in accurate effect site concentrations. The central PK compartment in Fig. 1 represents the infusion site and local blood vessels, such as the heart and lungs. The peripheral compartment can be thought of as the peripheral parts of the body to which blood flows, such as the legs and arms, and incorporating the fatty tissues into which these drugs and/or metabolites can be deposited. The effect site concentration is that region in which the drug exerts its primary effect. For drugs affecting the central nervous system, such as Morphine and Midazolam, the cerebro-spinal-fluid [24], or the brain [25, 26], is an acceptable representation of the effect site. 

Clinical trials investigating the PK of Morphine show that concentration profiles in healthy and ICU subjects are best approximated by a 3-compartment model [24, 27]. These studies attempt to model the PK of intravenous (I.V.) Morphine incorporating the effect of metabolites such as Morphine-3-glucuronide (M3G) and Morphine-6-glucuronide (M6G) by adding additional compartments. However, the analgesic and sedative effects of these metabolites are not easily quantified and the details of their pharmacological effect are not yet fully understood [25, 28, 29]. Further, metabolite concentrations have been shown to be small when administration techniques bypassing the first-pass effect are used, such as I.V. administration [28]. Therefore, this portion of the model uses three compartments and does not model the formation, distribution or secondary effect of Morphine metabolites. 

Clinical trials investigating the PK of I.V. Midazolam show that concentration profiles in healthy and ICU subjects are best approximated by a 2-compartment model [30-32]. While the activity of the major metabolite of Midazolam, alpha-hydroxy-midazolam (α-OH Midazolam) has received a lot of attention, the effect has not yet been fully defined [1, 33-35]. Therefore, this portion of the model uses two compartments and does not model the formation, distribution or secondary effect of metabolites. 

The overall model defined in Equations (1)-(6) consists of several PK and PD components. The PK parameters form the basis for the drug distribution and elimination half-life, while the PD parameters define the shape of the response surface and drug sensitivities. It is commonly accepted that significant inter-patient variability is observed in the pharmacology of sedatives in the critically ill and elderly [6, 36]. However, studies have also shown that inter-patient variability appears to be due primarily to variations in PD parameters, such as drug sensitivity, rather than PK parameters, such as drug clearance or volume of distribution [20, 37-39]. Therefore, identical PK parameters representative of a typical ICU patient were obtained from the literature [24, 27, 31, 32] and applied across all patients.

2.1.2 Pharmacodynamic (PD) Modelling
Midazolam is a commonly used sedative agent that can be used to induce anaesthesia or induce conscious sedation, depending on selected dose [31, 36]. Morphine, while primarily an analgesic, is also a mild sedative [6, 40]. However, Morphine and Midazolam, administered concomitantly, synergistically have an overall combined effect greater than the simple sum of the two individual effects [41, 42]. Furthermore, the effects of Morphine and Midazolam are typically not linearly proportional to drug concentrations, and instead behave like the well-known sigmoid concentration-effect relationship [23, 43, 44]. 

The combined PD effect of these drugs is modelled in Equation (6) using a response surface for drug interactions [23], incorporating synergism and effect saturation, as shown in Fig. 1. The sedative effect on the vertical axis lowers awareness, relieving anxiety and reducing agitation. Finally, Equation (6) captures the cumulative sedative effect of the drugs on the brain over time, and provides the relationship between stimulus invoking agitation and the sedative agents employed to manage agitation.

The non-linear pharmacodynamic (PD) Equation (6) is based on physiological observations of patient behaviour. It states that the rate of change of agitation depends upon the relative magnitude of the stimulus to the cumulative sedative effect and endogenous agitation reduction. Observed agitation typically falls upon increased infusion of sedative agents. Similarly, patients become more agitated by increased stimulus if infusion rates are not increased. Patient agitation is therefore primarily reduced by the cumulative impact of current and prior sedation administration, as modelled by the convolution integral in Equation (6). 

The final term in Equation (6) represents the effect of the endogenous opioid biochemical compounds, endorphins. Abbreviated from “endogenous morphine”, endorphins are a form of natural analgesic produced in response to pain and physical stress [45, 46]. An agitated patient may therefore experience a reduction in agitation due to the natural sedative effect of endorphins produced as result of agitation itself, modelled by the EAR term, -w3A, in Equation (6). This term is unique in comparison to prior works and represents a dynamic by which agitation can decline without the presence of exogenous sedative. Such a dynamic is a stabilising factor and would be significant during periods of low or no exogenous sedative input.

PD parameters, such as w2(t), w3, and, can vary widely between patients, and are fitted using recorded drug infusion profiles for each patient. The general shape of the PD response surface in Fig. 1 [23] is approximated by information in the literature [37, 38]. In particular, the response surface is defined to capture the synergistic sedative effects observed when Morphine and Midazolam are administered concomitantly [41, 42], the mild sedative effect of Morphine alone [6, 40], and saturation dynamics.

C50 represents the concentration at which the drug, administered alone, would have 50% effect. Using the PK model parameters and employing the recorded infusion rate, Equations (1)-(5) yield Morphine and Midazolam effect-site concentration profiles. These profiles can be used to estimate a patient-specific C50 value, assuming that clinical effect site concentration rarely becomes completely saturated. Natural initial estimates for C50 would be either the average, or 50% of the maximum, effect-site drug concentration from Equations (3) and (5). However, the impact of the synergistic effect surface means that the total combined effect of the drugs is higher than the simple sum of the individual drug effects, more regularly resulting in effect saturation. As a result, setting C50 to be 80% of the max effect site concentration provides an effective estimate. 

An integral-based fitting method is adapted from Hann et al [47], to obtain the patient-specific, time-varying, sedative sensitivity parameter, w2(t), and a patient-specific, time-invariant w3 EAR parameter from clinical data. Initial studies investigating the sensitivity of the model to changes in w3 indicated that small changes (i.e. less than an order of magnitude) had no observed effect on performance metrics. Therefore, the EAR parameter, assumed to be patient-specific, is selected for each patient from an array of values w3=[0 0.00001 0.0001 0.001]. All remaining model parameters used in this paper are taken from previous work [17, 19-21].

2.2 Model Verification
Equations (1)–(6) are implemented in conjunction with a validated nurse sedation control model that accurately captures the basic nursing sedation administration response to patient agitation using a simple derivative-weighted Proportional-Derivative controller [17, 19]. This simple nurse controller captures the basic psychology behind subjective assessments [20, 48], and closes the feedback loop between clinically observed or simulated agitation and sedation delivery, matching current clinical practice. Comparison of recorded infusion data with infusion profiles from simulations using fitted parameters provides a basis for statistically validating the model presented.

Infusion data were recorded using an electronic drug infusion device [10, 49] for all ICU patients admitted to the ICU during a nine month observation period and requiring more than 24 hours of sedation. Infusion data containing less than 48 hour of continuous data, or data from patients whose sedation requirements were extreme, such as those with severe head injuries, were excluded. A total of 37 ICU patients met these requirements and were enrolled in this study. Approval was obtained from the Canterbury Ethics Board for this research.

The unknown nature of pain and anxiety, combined with disease state, makes direct recording of stimulus profiles impossible. However, the input for the semi-automatic sedation infusion system implemented in the Christchurch ICU [10, 49] is the bedside medical staff’s indication of observed agitation, and therefore demand for additional drug. These recordings indicate times where the patient’s agitation level increased enough to warrant additional sedative, implying the presence of stimulus. It therefore forms the basis for a surrogate measure of stimulus for model validation [17]. The 4-hour moving average of this record retains the underlying structure of the recording, while creating a smooth stimulus profile congruent with recorded data. Note that clinical implementation of agitation feedback control of sedation would not require this input profile, requiring only measured agitation to determine the infusion needed. Hence, this is a model validation tool only.

One approach to model verification uses kernel smoothing of the recorded data to create a probability band using Chebychev’s inequality, and compares the simulated infusion profile to the probability band [17]. The higher the percentage of time that the simulated infusion profile lies within the band, the better the model is considered to capture the essential dynamics of the underlying system for that patient. While this approach is graphically useful, it lacks an objective numerical measure of how close the simulated infusion profile is to the empirical data. The percentage time in band (TIB) does not serve this purpose because it simply quantifies visual closeness by means of artificial hard boundaries, and ignores the fact that the in-band region does not have the same probabilistic importance everywhere. 

This paper utilises the statistical measure Relative Average Normalised Density (RAND), which indicates whether the simulated infusion profile coincides with a region of high probability determined from the recorded empirical data. RAND takes values between 0 and 1, where a value close to 1 means that the simulated infusion profile is, on average, in a high probability region and hence in good agreement with the empirical data. This measure effectively replaces the hard boundaries of the probability band by soft boundaries defined by probabilistic importance determined from the empirical data. Specific details on the development of the RAND metric can be found in the relevant literature [17, 20, 50-54].
RAND measures how probabilistically similar the model outputs are to the smoothed data, and hence the degree of compatibility between the model and the empirical data. For example, a RAND of 0.6 may be interpreted as the model outputs being 60% similar, on average, to the smoothed data. Since the model is deterministic, its outputs do not come from the same probabilistic mechanism that generated the recorded data. Hence, RAND is an extremely stringent measure, and consistently high RAND values close to 1 are not expected. A reasonable and practical threshold for adequate model performance is RAND ≥ 0.5, which says that the model outputs are more similar than not, to the smoothed data. If comparing two or more models to the data, the model with the higher RAND value would be selected. In this case, with one model, the threshold is 0.5. 

Finally, Relative Total Dose (RTD) expresses the total dose administered in the simulation as a percentage of the actual total recorded dose [17]. Ideally, this metric would approach 100%, indicating that the simulated total drug dose is identical to the recorded total drug dose. RTD, TIB and RAND are different objective measures of the ability of the model to capture the essential dynamics of the agitation-sedation system. Together, they create a clear picture of the model’s performance.

2.2 Analyses




The w3 value corresponding to the best fit between the simulated and recorded data was w3=0.0001 for all patients. The performance metrics in Table 1 show high values for the model with (w3=0.0001) and without (w3=0) EAR. The RAND values for simulations without EAR have a median of 0.77 with standard deviation 0.08 and range [0.51, 0.89]. TIB without EAR has a median of 0.87 with standard deviation of 0.05 and range [0.78, 0.97], while RTD has a median of 98.7 with standard deviation 2.1 and range [93.1, 101.4]. Similarly, the RAND values for simulations including EAR have a median of 0.78 with standard deviation 0.07 and range [0.55, 0.91]. TIB including EAR has a median across all patients of 0.89 with standard deviation of 0.04 and range [0.81, 0.97], and RTD has a median of 98.6 with standard deviation 2.1 and range [92.5, 101.0]. For w3 =0.00001 slightly lower values of the performance metrics were observed, and for w3 = 0.001 much lower values were observed.





The statistical model validation metric, RAND, complements and completes the other statistical tools (RTD and TIB) previously employed [17, 19-21] for model validation of this system. The probability band with hard boundaries developed previously allows visual assessment and numerical TIB evaluation, which is useful during model development and refinement. The RTD value simply represents a global assessment of the similarity of the resulting infusion rates to clinical data. In contrast, RAND provides an objective, calibrated measure of statistical compatibility between the simulated infusion profile and the recorded data. It thus provides a statistical measure of how well the model captures the essential dynamics of the agitation-sedation system. Together, all three metrics (RAND, TIB and RTD) cover a range of model validation criteria.

The best fit between the simulated and recorded data was obtained using w3=0.0001 for each and every patient, which shows the low inter-patient variability and low sensitivity to the EAR parameter, and indicates that w3 can be assumed constant across all patients. The sensitivity of the model to the value of w3 is reduced further by the fitting process for w2(t), which can compensate for potentially slightly incorrect selection of w3 [47]. This insensitivity in the EAR parameter is also seen for the similar term in the glucose-insulin system modelling [55]. Hence, it might be expected.

The impact of EAR can be seen by comparing columns 2 and 3 to columns 5 and 6 in Table 1. The median and upper and lower quartiles of the RAND and TIB for the model including EAR are all higher than those without EAR, and the standard deviations of these metrics are reduced for the model including EAR. These results indicate that the addition of the EAR dynamic improves the ability of the model to capture the observed dynamics of the agitation-sedation system.

The upper plot in Figures 2-4 show that while the difference is small, the inclusion of EAR results in a slight decrease in w2(t) throughout the entire profile, especially where infusion rates in the lower plot are very low. This result should be expected since the EAR dynamic is another form of agitation decrease thus reducing the sedative sensitivity required to match the clinical data when it is included. Note that when infusion rates are very low the primary means of agitation reduction would be EAR. Hence, the model that includes EAR has the greatest effect during periods of low sedation infusion where there is less exogenous agitation reduction. Such periods of low infusion, where the EAR dynamic is most important, would most notably include sedative weaning prior to extubation.

Visually, the lower plots on Figs. 2–4 show that the current model produces infusion profiles that are a close approximation to the recorded infusion profiles. The fact that the solid and dotted dark lines on the bottom plot in these figures are difficult to distinguish indicates that the simulated infusion rates are very similar whether EAR is included or not. High median RAND values for both models of 0.77 (without EAR) and 0.78 (with EAR), support this visual finding with a statistically-based objective measure.  Minimum RAND values of 0.51 and 0.55 for the two respective models reinforce this result. These results support both models as a valid representation of the fundamental agitation-sedation dynamics present in a broad spectrum of ICU patients. 

While the addition of the EAR dynamic increases the ability of the model to capture the observed dynamics of the agitation-sedation system, the improvement is relatively small when assessed globally across entire records. Further, the sensitivity of the model to the w3 parameter is low, a feature also found for non-drug mediated endogenous removal mechanisms in similar dynamic systems such as the glucose-insulin system [47, 55]. This result offers the question of whether the EAR dynamic should be included at all. It may be possible that the errors and assumptions in the development of the model and the performance metrics are larger than the difference in performance between the model with and without EAR. Although this issue may represent a limitation of the model, it is important to note that the inclusion of EAR is important for accurately capturing periods of low, or no, sedative infusion, such as weaning. In addition, visual inspection of results show that in periods of low or no infusion the impact is greater than elsewhere.

The performance parameters summarized in Table 1 were achieved using very few patient-specific PD parameters and identical PK parameters across all patients. This result supports the idea that interpatient pharmacological variability is due primarily to PD differences rather than PK differences, as reported in several studies [20, 38, 39]. However, the insensitivity of the w3 parameter and its smaller impact on results indicate that EAR is not a significant PD parameter in this case. However, EAR becomes important when simulating low infusion rates, such as during weaning. Therefore, although EAR is not always a significant dynamic, it is important during specific clinical periods. Because it has no negative impact during other periods it should be retained.

For some patients high w2 values are observed immediately after periods of relatively constant w2, as seen in Figure 2-4. Although this feature is sometimes located centrally in recorded data, in many cases this feature is observed at the end of recorded data and may correspond to weaning off sedation. These observations may be the result of a change in sedative sensitivity as the patient’s health improves prior to them leaving the ICU. 

However, the magnitudes of the changes are in some cases quite large, which indicates that the change in observed sedative sensitivity may also be the result of a delayed release of drugs stored in fatty tissue or the effects of active metabolites. Although the peripheral compartment represents the fatty tissues into which these drugs and/or metabolites can be deposited, this dynamic may be considerably more prominent than that currently modelled, requiring an additional separate storage compartment. Because benzodiazepines are lipid soluble, long-term infusions can lead to depositions of large amounts of the administered drug in fatty tissues [56]. When the sedative administration stops, the stored drug is released back into circulation [2, 6, 56]. Alternatively, these effects may be due to the prolonged action of active metabolites. If these dynamics were present during the recordings, the effect would be an inflated observed sedative sensitivity, w2.  

To determine if a relationship exists between the improvement resulting from the EAR dynamic and the duration of the infusion, a correlation analysis was undertaken. The correlation between the improvement resulting from inclusion of the EAR dynamic and the duration of infusion was determined using the non-parametric bootstrap (Efron et al, 1993), which does not require a parametric distribution for the data. The correlation coefficient  was found to be r=-0.007, with 95% confidence interval bounds of (-0.246 , 0.398), and P=0.968, indicating that there is almost 97% chance that correlation exists. Although there is a lack of correlation, this does not imply that delayed release of drugs stored in fatty tissue or the effects of active metabolites are not present. Further investigation is required to determine the effect of an additional storage dynamic and active metabolites.






The physiological model presented captures the essential dynamics of the agitation-sedation system, both with and without the Endogenous Agitation Reduction (EAR) term. High median RAND values of 0.77 (without EAR) and 0.78 (with EAR) support and minimum RAND values of 0.51 and 0.55 for the two respective models show that both models are valid representations of the fundamental agitation-sedation dynamics present in a broad spectrum of ICU patients. 
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FIGURE & TABLE CAPTIONS
Fig. 1.	Representation of the agitation-sedation system model, showing separate compartmental pharmacokinetics (upper portion), the pharmacodynamic effect surface with the associated defining equation [21].
Fig. 2. 	Plot showing the effect of endogenous agitation reduction (EAR) on sedative sensitivity,w2(t),(upper plot), and fit to recorded infusion rate (lower plot) for Patient 2. The dark solid line shows the results without the inclusion of EAR, and the dark dotted line shows the results including EAR. The light solid line in the lower plots shows the recorded infusion rate, and its 99% probability band is indicated by the grey band.
Fig. 3. 	Plot showing the effect of endogenous agitation reduction (EAR) on sedative sensitivity,w2(t),(upper plot), and fit to recorded infusion rate (lower plot) for Patient 37. The dark solid line shows the results without the inclusion of EAR, and the dark dotted line shows the results including EAR. The light solid line in the lower plots shows the recorded infusion rate, and its 99% probability band is indicated by the grey band.
Fig. 4. 	Plot showing the effect of endogenous agitation reduction (EAR) on sedative sensitivity,w2(t),(upper plot), and fit to recorded infusion rate (lower plot) for Patient 36. The dark solid line shows the results without the inclusion of EAR, and the dark dotted line shows the results including EAR. The light solid line in the lower plots shows the recorded infusion rate, and its 99% probability band is indicated by the grey band.











































Table 1. Validation metrics for 37 patients for simulations with and without EAR
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